World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
62
Citations
16331
World Ranking
3116
National Ranking
1460

Jean D. Boyer publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jean D. Boyer sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 200 publications — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jean D. Boyer D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jean D. Boyer sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 62 D-Index — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Jean D. Boyer is affiliated with Inovio Pharmaceuticals in the United States and has a research career focused primarily on medicine and immunology and microbiology. Their work spans multiple subfields including infectious diseases, immunology, oncology, epidemiology, and biotechnology.

The main topics addressed in Boyer's research include SARS-CoV-2 and COVID-19 research, immunotherapy and immune responses, cancer immunotherapy and biomarkers, CAR-T cell therapy research, COVID-19 clinical research studies, SARS-CoV-2 detection and testing, and animal virus infections studies.

Recent notable publications by Boyer include the following:

  • "Immunogenicity of a DNA vaccine candidate for COVID-19" (2020) in Nature Communications
  • "Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial" (2020) in EClinicalMedicine
  • "SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial" (2022) in The Journal of Infectious Diseases
  • "A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer" (2020) in International Journal of Radiation Oncology*Biology*Physics
  • "INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants" (2021) in npj Vaccines

Frequent coauthors collaborating with Boyer include:

  • David B. Weiner
  • Matthew P. Morrow
  • Albert J. Sylvester
  • Laurent Humeau
  • Kimberly A. Kraynyak

Common publication venues for Boyer's work are:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research
  • Nature Communications
  • npj Vaccines
  • Vaccines

Best Publications

  • Gene inoculation generates immune responses against human immunodeficiency virus type 1.

    Bin Wang;Kenneth E. Ugen;Vasantha Srikantan;Michael G. Agadjanyan

  • Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

    Cornelia L Trimble;Matthew P Morrow;Kimberly A Kraynyak;Xuefei Shen

  • First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response

    Rob Roy MacGregor;Jean D. Boyer;Kenneth E. Ugen;Kim E. Lacy

  • Immunogenicity of a DNA vaccine candidate for COVID-19.

    Trevor R.F. Smith;Ami Patel;Stephanie Ramos;Dustin Elwood

  • Gene transfer in humans using a conditionally replicating lentiviral vector

    Bruce L. Levine;Laurent M. Humeau;Jean Boyer;Rob-Roy MacGregor

  • Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

    Jean D. Boyer;Kenneth E. Ugen;Bin Wang;Michael Agadjanyan

  • In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen.

    Jong J. Kim;Velpandi Ayyavoo;Mark L. Bagarazzi;Michael A. Chattergoon

  • Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses

    Mark L. Bagarazzi;Jian Yan;Matthew P. Morrow;Xuefei Shen

  • Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

    Kayvon Modjarrad;Christine C. Roberts;Kristin T. Mills;Amy R. Castellano

  • CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines.

    Jong J. Kim;Liesl K. Nottingham;Jeong I. Sin;Anthony Tsai

  • Modulation of amplitude and direction of in vivo immune responses by co‐administration of cytokine gene expression cassettes with DNA immunogens

    Jong J. Kim;Neil N. Trivedi;Liesl K. Nottingham;Lake Morrison

  • Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes

    Jong J. Kirn;Mark L. Bagarazzi;Neil Trivedi;Yin Hu

  • Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells.

    Michael A. Chattergoon;Tara M. Robinson;Jean D. Boyer;David B. Weiner

  • Standardization of cytokine flow cytometry assays

    Holden T Maecker;Aline Rinfret;Patricia D'Souza;Janice Darden

  • Modulating the immune response to genetic immunization.

    Adam. D. Cohen;Jean D. Boyer;David B. Weiner

  • Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report.

    Pablo Tebas;Christine C. Roberts;Kar Muthumani;Emma L. Reuschel

  • Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

    Spyros A. Kalams;Scott D. Parker;Marnie Elizaga;Barbara Metch

  • Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.

    Leonel Maldonado;Jessica E. Teague;Matthew P. Morrow;Iveta Jotova

  • Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.

    Pablo Tebas;Shu Ping Yang;Jean D. Boyer;Emma L. Reuschel

  • In Vivo Modulation of Vaccine-Induced Immune Responses toward a Th1 Phenotype Increases Potency and Vaccine Effectiveness in a Herpes Simplex Virus Type 2 Mouse Model

    Jeong-Im Sin;Jong J. Kim;Jean D. Boyer;Richard B. Ciccarelli

  • Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help.

    Michele A. Kutzler;Tara M. Robinson;Michael A. Chattergoon;Daniel K. Choo

Frequent Co-Authors

David B. Weiner
David B. Weiner The Wistar Institute
Kenneth E. Ugen
Kenneth E. Ugen University of South Florida
Niranjan Y. Sardesai
Niranjan Y. Sardesai University of Pennsylvania
William V. Williams
William V. Williams GlaxoSmithKline (United Kingdom)
Pablo Tebas
Pablo Tebas University of Pennsylvania
George N. Pavlakis
George N. Pavlakis Emory University
Karuppiah Muthumani
Karuppiah Muthumani The Wistar Institute
Mark G. Lewis
Mark G. Lewis Walter Reed Army Institute of Research
Rob Roy MacGregor
Rob Roy MacGregor University of Pennsylvania
Carl H. June
Carl H. June University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Immunology in the USA can lead to a variety of exciting career paths, particularly in healthcare and research. For those interested in nursing, several online degree options provide accessible entry points. Non-nurses looking to enter the field can benefit from online adn programs for non nurses, which offer flexible routes to earning a foundational nursing credential.

Additionally, accelerated programs can be a great choice for individuals seeking a faster transition into nursing roles. The easiest accelerated nursing programs to get into provide streamlined pathways tailored for students with prior education or experience.

For those starting with practical nursing, exploring lpn programs easy to get into can offer a manageable entry-level credential that supports hands-on patient care roles. Further advancement is possible through easiest np program options, which prepare nurses for advanced practice and expanded responsibilities.

Ultimately, combining a solid foundation in Immunology with targeted nursing qualifications opens up diverse professional opportunities, from clinical practice to specialized healthcare research. Choosing the right online program based on accessibility and career goals is key to success in this evolving field.

Best Scientists Citing Jean D. Boyer

Trending Scientists

Recently Published Articles